Macleods Pharma USA Recalls Nearly 4,000 Bottles of Blood Pressure Medication
Just the facts

Macleods Pharma USA Recalls Nearly 4,000 Bottles of Blood Pressure Medication

Summary

The FDA announced a Class II recall of 3,744 bottles of olmesartan, amlodipine and hydrochlorothiazide tablets after the manufacturer reported failed dissolution specifications.

The U.S. Food and Drug Administration has issued a Class II recall for 3,528 thirty-count bottles and 216 ninety-count bottles of a combination blood-pressure tablet containing olmesartan medoxomil, amlodipine and hydrochlorothiazide. The recall was initiated by Macleods Pharma USA, Inc. on Oct. 7 after the company found the products did not meet dissolution specifications, meaning the active ingredients may not be released properly in the body.

The FDA said the defect could lead to temporary or medically reversible health effects. Affected products are labeled with NDC 33342-246-07 (30-count) and 33342-246-10 (90-count), lot numbers 12251163A and 12251163B, and carry an expiration date of May 31, 2027.

Consumers are advised to check their medication bottles for the listed identifiers and to follow the FDA’s guidance on returning or disposing of the recalled tablets.

"The recall is being conducted voluntarily by the manufacturer and is intended to protect public health," the FDA statement read.

Keep reading — for free

Create a free account to follow the news. No card required.